Vnitr Lek 2010, 56(10):1078-1081

Treatment of an obese diabetic

©. Svačina
III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. ©těpán Svačina, DrSc., MBA

Weight reduction is an important component of comprehensive management of diabetes. Weight reduction can be achieved using 6 methods: 1. diet 2. physical activity, 3. psychotherapy, 4. bariatric surgery, 5. pharmacotherapy of obesity, 6. selection of an appropriate antidiabetic medication. Orlistat is the only antiobesity agent presently available in the Czech Republic. Weight neutral (metformin and gliptins) and weight reducing antidiabetics (incretine analogues exenatide and liraglutide) and insulin analogue detemir are suitable antidiabetic drugs. We thus have a sufficient range of options available for weight reduction in diabetic patients.

Keywords: obesity; diet therapy; bariatric surgery; antiobesity medication; liraglutid; exenatid; levemir; metformin

Received: June 11, 2010; Published: October 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svačina ©. Treatment of an obese diabetic. Vnitr Lek. 2010;56(10):1078-1081.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lean ME, Powrie JK, Anderson AS et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7: 228-233. Go to original source... Go to PubMed...
    2. Fried M, Svačina ©, Owen K. Bariatrická chirurgie a diabetes. Trendy v diabetologii 10. Praha: Galén 2005.
    3. Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248-256. Go to original source... Go to PubMed...
    4. Svačina © et al. Klinická dietologie. Praha: Grada 2008.
    5. Regensteiner JG, Reusch JE, Stewart KJ et al. Exercise and Diabetes. New York: Humana Press 2009.
    6. Svačina ©. Obezita a diabetes. Praha: Maxdorf 2000.
    7. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994-1003. Go to original source... Go to PubMed...
    8. ©mahelová A. Výsledky multicentrického sledování léčby sibutraminem u obézních diabetiků v České republice. Vnitř Lék 2005; 51: 676-680.
    9. Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin Pharmacother 2007; 8: 1733-1742. Go to original source... Go to PubMed...
    10. Svačina ©. Prevence diabetu a jeho komplikací. Praha: Triton 2008.
    11. Nathan DM, Davidson MB, DeFronzo RA et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753-759. Go to original source... Go to PubMed...
    12. Svačina ©. Systémové účinky metforminu. Postgrad Med 2010.
    13. Martin S, Kolb H, Beuth J et al. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 2003; 46: 1611-1617. Go to original source... Go to PubMed...
    14. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28: 1107-1112. Go to original source... Go to PubMed...
    15. Svačina © et al. Metabolický syndrom. Praha: Triton 2006.
    16. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007; 9: 31-38. Go to original source... Go to PubMed...
    17. Haluzík M, Svačina ©. Inkretinová léčba diabetu. Praha: Mladá Fronta 2010.
    18. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-286. Go to original source... Go to PubMed...
    19. Bhushan R, Elkind-Hirsch KE, Bhushan M et al. Exenatide use in the management of metabolic syndrome: a retrospective database study. Endocr Pract 2008; 14: 993-999. Go to original source... Go to PubMed...
    20. Astrup A, Rössner S, Van Gaal L et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616. Go to original source... Go to PubMed...
    21. Svačina ©. Potenciální nová antidiabetika v příątím desetiletí. Vnitř Lék 2009; 55: 429-433. Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.